See "Qualified therapies in CLL: mechanisms of resistance and techniques for management" on webpage 471. Duvelisib was the second PI3K inhibitor permitted with the FDA, also depending on a stage III randomized demo.one hundred thirty The efficacy and basic safety profile in the drug seem similar with These of idelalisib, https://franka110ufn3.wikidirective.com/user